These data indicate that splicing defects in the MyoD-DM1-hiPSC-derived myotubes can be identified by the modified culture protocol and that analysis on day 17 would be appropriate for evaluation of the drug efficacy. Here, MYOD1 is linked to myotonic dystrophy type 1.